冰火两重天！化工、有色强者恒强，科技股延续低迷，资金去向何方？

Market Overview - A-shares experienced volatility on February 6, with the Shanghai Composite Index closing down 0.25% at 4065.58 points, and the ChiNext Index down 0.73% [1] - The overall market turnover decreased to 2.16 trillion yuan, marking a continuous six-day decline in trading volume [1] Sector Performance - The chemical and new energy sectors led the market, while the pharmaceutical sector showed relative resilience. Consumer goods experienced a pullback, and technology continued to be sluggish [1] - The chemical ETF (516020) saw a significant inflow of 199 billion yuan, with a daily gain of 2.37% after reaching a peak increase of 3.45% during the day [2][5][6][8] Chemical Sector Insights - The chemical sector is experiencing a strong upward cycle, driven by increased demand for lithium batteries and key chemical materials [9][10] - Major stocks in the chemical sector, such as Enjie Co., Ltd. and Zhejiang Longsheng, saw significant gains, with some stocks rising over 6% [6][9] Non-Ferrous Metals Sector - The non-ferrous metals sector demonstrated resilience, with the non-ferrous ETF (159876) reversing early losses to close slightly up by 0.18% despite fluctuations in international gold prices [3][11] - Over 100 billion yuan of main funds flowed into the non-ferrous metals sector, indicating strong investor interest [11] Hong Kong Market Dynamics - The Hong Kong market experienced a downward trend, with the Hang Seng Index and Hang Seng Tech Index both closing down over 1% [3] - Despite the overall decline, there was significant buying activity from southbound funds, with purchases reaching 133.7 billion HKD, 249.8 billion HKD, and 148.6 billion HKD over three days [4] Pharmaceutical Sector Developments - The Hong Kong pharmaceutical sector showed signs of recovery, with the innovative drug ETF (520880) rising by 2% during the day, driven by strong earnings forecasts from key companies [15][16] - Notable performers included Innovent Biologics, which projected a revenue increase of approximately 134% by 2025, and several other companies expecting significant profit growth [16][18] Investment Opportunities - Analysts suggest that the chemical sector remains a promising investment opportunity, particularly in leading companies and price recovery products [10][22] - For investors looking to capitalize on the pharmaceutical sector, the innovative drug ETF (520880) and the medical ETF (159137) are recommended for their strong growth potential and coverage of key industry players [21][22]